This FcRn-based principle of cancer targeting by drug-carrying HSA has been demonstrated on pancreatic cancer cell lines and their derived xenografts with a DOX–HSA conjugate via an acid-sensitive linker [41]. This evidence concerns the gene FCGRT and cancer.